| Literature DB >> 26813689 |
M Schmalzing1, M Krockenberger2, A Honig3, H-P Tony4.
Abstract
The risk of gynecological cancers in patients with inflammatory rheumatic diseases only seems to be elevated with respect to cervical cancer and mainly in patients with systemic lupus erythematosus. There is increasing evidence for an influence of the immune system on tumor control of gynecological malignancies; however, an adverse influence of immunosuppressive treatment in rheumatic patients was indicated only for the risk of cervical cancer. In contrast, biologics could not be shown to cause an increased risk of cervical cancer but data on this topic are limited. General screening recommendations exist for breast cancer and cervical cancer. Recommendations for follow-up after oncological treatment are presented. Because of limited evidence immunosuppressive and biological treatment should be applied with great restraint at least within the first 5 years after curative oncological treatment also for gynecological tumors. As far as breast cancer is concerned an even longer interval is under discussion.Entities:
Keywords: Breast cancer; Cervical cancer; Immunosuppression; Ovarian cancer; Systemic lupus erythematosus
Mesh：
Substances：
Year: 2016 PMID： 26813689 DOI： 10.1007/s00393-016-0044-z
Source DB: PubMed Journal: Z Rheumatol ISSN： 0340-1855 Impact factor: 1.372